Launched in 2011, the CRACK IT Challenge programme spearheads the development of innovative 3Rs technologies by responding directly to the needs of end-users across the biosciences. The Challenges have delivered products and services for the improvement of scientific data, increase the predictivity of models and reduce the reliance on animals.
2022 Challenge launch
This webinar will launch the 2022 CRACK IT Challenge 42 – T-ALERT: animal-free tumourigenicity assessment of CAR-T and other genetically modified T cells.
CAR-T (chimeric antigen receptor T-cell) therapies are emerging as an effective therapeutic approach in the treatment of some cancers. In vivo studies are used to assess the potential for tumourigenicity of these therapies and are invasive and often not predictive of clinical outcome. This Challenge aims to develop an in vitro assay that can reliably evaluate tumourigenicity of human-engineered T cell therapies with the potential to be applied to multiple immune cell types.
T-ALERT is a Two Phase Challenge sponsored by Novartis, Takeda, AstraZeneca, Sonomabio and GentiBio. Further information about this Challenge can be found on the NC3Rs Innovation Platform.
The webinar will give you an opportunity to learn more about the competition, ask the Sponsors questions and find out how to submit a competitive application.